

12<sup>th</sup> November, 2024

<b>BSE Limited</b> 1 <sup>st</sup> Floor, New Trading Ring, Rotunda Bldg, P.J. Towers, Dalal Street, Mumbai- 400 001 <u>Script Code: 500259</u>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, 5 <sup>th</sup> Floor, Plot No. C/1, G. Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 <u>Script Code: LYKALABS</u>
--	--

Dear Sir/Madam,

**Sub: Outcome of the Board Meeting – 12<sup>th</sup> November, 2024**

**Ref: Intimation under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( the SEBI Listing Regulations)**

We are pleased to inform you that the Board of Directors of the Company at its meeting held on today i.e. 12<sup>th</sup> November, 2024, has *inter-alia*, considered and approved the following matters:

- i. Un-audited Standalone and Consolidated Financial Results of the Company for the second quarter and half year ended 30<sup>th</sup> September, 2024 and the said Financial Results have been reviewed by the Audit Committee.

In this regard, a copy of the said Financial Results alongwith the Limited Review Reports of the Auditors of the Company thereon is enclosed herewith. These are also being made available on the website of the Company at [www.lykalabs.com](http://www.lykalabs.com)

- ii. Appointment of Mr. Shekhar R Singh, as Company Secretary & Compliance Officer and designated as a Key Managerial Personnel of the Company with effect from 12<sup>th</sup> November, 2024. The detailed disclosure as required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July 2023 is enclosed herewith .
- iii. Re-constitution of the Board Committees viz Audit Committee, Nomination & Remuneration Committee, Stakeholders Relationship Committee and Corporate Social Responsibility Committee with effect from 12<sup>th</sup> November, 2024. The detailed composition of the Board Committees (after re-constitution) is enclosed herewith.

The meeting of the Board of Directors commenced at 11.45 am and concluded at 12:40 p.m.

Kindly take the same on your record.

Thanking You,

Yours faithfully,

**For Lyka Labs Limited**

**Kunal Gandhi**  
**Managing Director**

DIN: 01516156

Encl.: as above

## Statement of Standalone Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2024

(₹ in lakh)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30th September, 2024	30th June 2024	30th Sep, 2023	30th September, 2024	30th Sep, 2023	31st March, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>I. Revenue</b>						
Revenue from Operations	4115.51	3010.47	2676.00	7125.98	4799.70	10639.63
Other Income	12.94	61.95	30.45	74.89	73.28	164.72
	<b>4128.45</b>	<b>3072.42</b>	<b>2706.45</b>	<b>7200.87</b>	<b>4872.98</b>	<b>10804.35</b>
<b>II. Total Income</b>						
<b>III. Expenses</b>						
(a) Cost of Materials Consumed	1020.38	777.53	839.03	1797.91	1448.45	3214.31
(b) Purchase of Stock in trade	821.73	400.09	233.62	1221.83	593.81	1158.47
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	(47.60)	(28.09)	48.04	(75.69)	(64.28)	(78.61)
(d) Employee benefits expense	820.42	803.50	620.94	1623.92	1187.50	2601.46
(e) Finance Costs	51.73	65.07	117.08	116.80	250.40	479.79
(f) Depreciation and amortisation expense	168.34	167.70	346.32	336.04	679.86	1228.71
(g) Other expenses	966.63	652.05	540.88	1618.68	984.95	2287.95
<b>Total Expenses</b>	<b>3801.63</b>	<b>2837.85</b>	<b>2745.89</b>	<b>6639.49</b>	<b>5080.69</b>	<b>10892.08</b>
<b>IV. Profit / (Loss) before Exceptional Items and Taxes (II - III)</b>	<b>326.82</b>	<b>234.58</b>	<b>(39.44)</b>	<b>561.38</b>	<b>(207.71)</b>	<b>(87.73)</b>
<b>V. Exceptional Items (Net)</b>	0.00	0.00	4.52	0.00	4.52	5.51
<b>VI. Profit / (Loss) before Tax</b>	<b>326.82</b>	<b>234.58</b>	<b>(43.95)</b>	<b>561.38</b>	<b>(212.22)</b>	<b>(93.24)</b>
<b>VII. Tax Expenses</b>						
Current Tax	84.41	40.00	10.00	124.41	33.50	159.97
Deferred Tax	(4.88)	19.61	(24.72)	14.73	(44.51)	(26.32)
<b>VIII. Net Profit / (Loss) after Tax</b>	<b>247.29</b>	<b>174.96</b>	<b>(29.23)</b>	<b>422.24</b>	<b>(201.22)</b>	<b>(226.89)</b>
<b>IX. Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)</b>	0.00	0.00	0.00	0.00	(1.57)	6.17
<b>X. Total Comprehensive Income / (Loss)</b>	<b>247.29</b>	<b>174.96</b>	<b>(29.23)</b>	<b>422.24</b>	<b>(202.79)</b>	<b>(220.72)</b>
Paid up Equity Share Capital (Face value ₹ 10/- each)	3569.00	3569.00	3309.00	3569.00	3309.00	3309.00
Other Equity						6623.91
<b>XI. Basic and diluted earnings per share</b>	<b>0.69</b>	<b>0.49</b>	<b>(0.10)</b>	<b>1.17</b>	<b>(0.63)</b>	<b>(0.72)</b>

### Notes:

- The above unaudited standalone financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 12th November 2024
- During the Half year ended September, 2024, balance 26,00,000 convertible warrants were converted into equity shares, on receipt of balance amount of 75% of the issue price of Rs.139.50 (including premium) per warrant. Further, such 26,00,000 equity shares were issued and allotted to Ipca Laboratories Limited. Accordingly, our Equity Capital and Securities Premium shall stand increased.
- The Company operates in one business segment i.e. "Pharmaceuticals".
- The figures for the previous year have been regrouped / rearranged wherever considered necessary.
- The Statutory Auditors have expressed an unqualified opinion on the unaudited Standalone financials results for the quarter and half year ended 30th September 2024.

For Lyka Labs Limited



**Kunal Gandhi**  
Managing Director & CEO  
DIN: 01516156

Mumbai : 12th November, 2024.

<b>Unaudited Statement of Assets &amp; Liabilities as at 30th September, 2024</b>		
(₹ in lakh)		
Particulars	As at 30th September, 2024	As at 31st March, 2024
<b>ASSETS</b>		
<b>1 Non-Current Assets</b>		
(a) Property, Plant and Equipment	4,728.41	4,579.93
(b) Capital Work- In- Progress	2,751.96	2,197.17
(c) Intangible assets	877.16	984.43
(d) Intangible assets under development	100.29	108.09
	<b>8,457.82</b>	<b>7,869.63</b>
(e) Financial Assets		
(i) Investments	3,240.30	3,240.30
(ii) Other Financial Assets	1,668.89	1,671.39
(f) Other Non Current Assets	630.32	746.06
(g) Non Current Tax Assets	72.00	74.63
	<b>5,611.51</b>	<b>5,732.38</b>
<b>2 Current Assets</b>		
(a) Inventories	967.96	955.83
(b) Financial Assets		
(i) Investments	1.86	1.71
(ii) Trade Receivables	3,742.61	2,572.86
(iii) Cash and Cash Equivalents	102.87	588.58
(iv) Loans	159.21	223.92
(v) Other Financial Assets	491.74	282.78
(c) Other Current Assets	407.17	360.68
	<b>5,873.42</b>	<b>4,986.36</b>
<b>Total Assets</b>	<b>19,942.75</b>	<b>18,588.37</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share capital	3,569.00	3,309.00
(b) Other Equity	9,506.40	6,623.90
	<b>13,075.40</b>	<b>9,932.90</b>
<b>LIABILITIES</b>		
<b>1 Non-Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	2,329.30	4,290.67
(ii) Lease Liabilities	125.84	125.84
(iii) Other Financial Liabilities	115.20	114.31
(b) Provisions	105.26	174.31
(c) Deferred Tax Liabilities (net)	387.29	372.56
	<b>3,062.89</b>	<b>5,077.69</b>
<b>2 Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	1,020.73	1,366.28
(ii) Lease Liabilities	40.10	82.22
(iii) Trade Payable		
- Micro and Small Enterprise	141.64	82.56
- Other than Micro and Small Enterprise	1,420.56	1,008.10
(iv) Other Financial Liabilities	859.34	774.83
(b) Other Current Liabilities	165.63	114.44
(c) Provisions	156.47	149.34
	<b>3,804.47</b>	<b>3,577.78</b>
<b>Total Equity and Liabilities</b>	<b>19,942.75</b>	<b>18,588.37</b>





**Lyka Labs Limited**  
**Unaudited Cash Flow Statement for the Half Year Ended 30th September, 2024**

Particulars	For the Half Year ended 30th September, 2024		For the Half Year Ended 30th September, 2023	
<b>A. Cash Flow from Operating Activities</b>				
Profit / (Loss) for the Year before tax		561.38		(212.23)
Adjusted for				
Depreciation	336.04		679.86	
Interest Income	(17.32)		(31.82)	
Finance Cost	116.80		250.40	
Provision for Employee Benefits	28.03		31.24	
Exchange rate fluctuation	(49.57)		(11.56)	
Exceptional Items	-		-	
Return on Investment	-		(0.03)	
		<b>413.98</b>		<b>918.09</b>
<b>Operating profit before working capital change</b>		<b>975.36</b>		<b>705.87</b>
<b>Changes in Working Capital :</b>				
Increase) / Decrease in Other Non-Current Financial Assets	2.50		(20.95)	
Increase) / Decrease in Other Non-Current Assets	115.74		(116.13)	
Increase) / Decrease in Inventories	(12.13)		(102.80)	
Increase) / Decrease in Trade and other receivables	(1,118.21)		(991.74)	
Increase) / Decrease in Other Current Financial Assets	(208.95)		79.86	
Increase) / Decrease in Other Current Assets	(46.49)		(71.72)	
Increase) / Decrease in Current Loans	64.71		323.29	
Increase) / (Decrease) in Other Non-Current Financial Liabilities	1.05		28.00	
Increase) / (Decrease) in Non-Current Provisions	(69.05)		(1.56)	
Increase) / (Decrease) in Trade Payables	471.54		264.18	
Increase) / (Decrease) in Other Current Financial Liabilities	88.95		(163.02)	
Increase) / (Decrease) in Other Current Liabilities	51.19		(41.47)	
Increase) / (Decrease) in Current Provisions	(22.87)		(17.99)	
		<b>(682.02)</b>		<b>(831.99)</b>
<b>Cash generated from operations</b>		<b>293.34</b>		<b>(126.13)</b>
Net Income Tax Payment	(121.78)	(121.78)	(46.30)	(46.30)
<b>Net cashflow from operating activities (A)</b>		<b>171.56</b>		<b>(172.43)</b>
<b>B. Cashflow for Investing activities</b>				
Purchase of Fixed Assets	(924.24)		(309.76)	
Increase in Investment	(0.15)		-	
Sale of Fixed Assets	-		-	
Interest Received	17.32		31.82	
<b>Net cash used in Investing activities (B)</b>		<b>(907.07)</b>		<b>(277.95)</b>
<b>C. Cashflow from Financing activities</b>				
Proceed from / (Repayment) of Non Current Borrowings Net	(1,975.36)		(1,882.64)	
Proceed from / (Repayment) of Current Borrowings Net	(373.85)		(160.51)	
Proceeds from Issue of Equity Shares and Warrants (Including Premium)	2,720.25		2,511.00	
Interest Paid	(121.24)		(476.08)	
<b>Net cash used in Financing activities (C)</b>		<b>249.80</b>		<b>(8.23)</b>
<b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b>		<b>(485.71)</b>		<b>(458.61)</b>
<b>Cash and Cash Equivalents at the beginning of the Year</b>				
Cash and Cash Equivalents		19.43		57.77
Earmarked Balances		569.17		811.79
		<b>588.60</b>		<b>869.58</b>
<b>Cash and Cash Equivalents at the end of the Year</b>				
Cash and Cash Equivalents		17.66		42.75
Deposits with Banks (Rs 85.22 lakhs Lien against Bank Guarantee)		85.22		368.14
		<b>102.88</b>		<b>410.89</b>




**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to  
The Board of Directors  
Lyka Labs Limited**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of **Lyka Labs Limited** (the "Company") for the quarter ended September 30, 2024 and year to date from April 1, 2024 to September 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations').
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For D. Kothary & Co.**  
Chartered Accountants  
Firm Regn No. 105335W

  
**Deepak O. Narsaria**  
(Partner)  
Membership No. 121190



UDIN: 24121190BK B0X14889

Place: Mumbai  
Date: 12th November, 2024



## Statement of Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2024

Rs. In Lakhs

Particulars	Quarter Ended			Half year Ended		Year Ended
	30th September, 2024	30th June 2024	30th September, 2023	30th September, 2024	30th September, 2023	31st March, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>I. Revenue</b>						
Revenue from Operations	4,115.51	3,011.40	2,798.65	7,126.91	5,086.35	11,119.46
Other Income	2.66	55.88	24.62	58.54	62.18	145.47
<b>II. Total Income</b>	<b>4,118.17</b>	<b>3,067.28</b>	<b>2,823.27</b>	<b>7,185.45</b>	<b>5,148.53</b>	<b>11,264.93</b>
<b>III. Expenses</b>						
(a) Cost of Materials Consumed	1,020.38	777.53	839.04	1,797.91	1,448.46	3,214.31
(b) Purchase of Stock in trade	821.73	400.75	282.04	1,222.49	735.93	1,349.36
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	(47.60)	(28.09)	47.94	(75.69)	(64.40)	(78.50)
(d) Employee benefits expense	834.90	818.77	643.70	1,653.67	1,237.22	2,676.54
(e) Finance Costs	54.30	64.71	118.77	119.01	253.91	489.09
(f) Depreciation and amortisation expense	176.30	175.66	359.47	351.96	706.16	1,280.18
(g) Other expenses	990.92	671.70	568.11	1,662.62	1,046.90	2,386.27
<b>Total Expenses</b>	<b>3,850.93</b>	<b>2,881.03</b>	<b>2,859.07</b>	<b>6,731.97</b>	<b>5,364.18</b>	<b>11,317.25</b>
<b>IV. Profit / (Loss) before Exceptional Items and Taxes (II - III)</b>	<b>267.25</b>	<b>186.25</b>	<b>(35.80)</b>	<b>453.48</b>	<b>(215.65)</b>	<b>(52.32)</b>
<b>V. Exceptional Items (Net)</b>	-	-	43.48	-	43.48	41.06
<b>VI. Profit / (Loss) before Tax</b>	<b>267.25</b>	<b>186.25</b>	<b>(79.28)</b>	<b>453.48</b>	<b>(259.13)</b>	<b>(93.37)</b>
<b>VII. Non Controlling Interest</b>	(18.52)	(15.06)	(12.96)	(34.06)	(21.38)	(13.12)
<b>VIII. Profit / (Loss) before Tax</b>	<b>285.77</b>	<b>201.31</b>	<b>(66.32)</b>	<b>487.54</b>	<b>(237.75)</b>	<b>(80.25)</b>
<b>IX. Tax Expenses</b>						
Current Tax / Earlier Year Tax	84.41	40.00	13.93	124.41	48.24	186.93
Deferred Tax	(8.29)	17.30	(31.60)	9.01	(52.67)	(18.26)
<b>X. Net Profit / (Loss) after Tax</b>	<b>209.65</b>	<b>144.01</b>	<b>(48.65)</b>	<b>354.12</b>	<b>(233.32)</b>	<b>(248.92)</b>
<b>XI. Other Comprehensive Income (Net of Tax) - Net Credit / (Charge)</b>	2.09	(0.34)	2.14	1.75	0.57	10.54
<b>XII. Total Comprehensive Income / (Loss)</b>	<b>211.74</b>	<b>143.67</b>	<b>(46.51)</b>	<b>355.87</b>	<b>(232.75)</b>	<b>(238.38)</b>
<b>XIII. Paid up Equity Share Capital (Face value Rs.10/- each)</b>	3,569.00	3,569.00	3,309.00	3,569	3,309.00	3,309.00
Other Equity						3,506.43
<b>XIV. Basic and diluted earnings per share</b>	0.58	0.40	(0.16)	0.98	(0.73)	(0.79)

**Notes:**

- The above unaudited consolidated financial results were considered by the Audit Committee in its meeting, which was approved and taken on record at the meeting of the Board of Directors; held on 12th November, 2024.
- During the Half Year ended Sep, 2024, balance 26,00,000 convertible warrants were converted into equity shares, on receipt of balance amount of 75% of the issue price of Rs.139.50 (including premium) per warrant. Further, such 26,00,000 equity shares were issued and allotted to Ipca Laboratories Limited. Accordingly, our Equity Capital and Securities Premium shall stand increased.
- The Company operates in one business segment i.e. "Pharmaceuticals".
- The figures for the previous year have been regrouped / rearranged wherever considered necessary.
- The Statutory Auditors have expressed an unqualified opinion on the unaudited Consolidated financials results for the quarter and Half Year ended 30th September, 2024.



For Lyka Labs Limited  
  
 Kunal Gandhi  
 Managing Director & CEO  
 DIN: 01516156

Mumbai; 12th November, 2024

## Unaudited Statement of Assets & Liabilities as at 30th September, 2024

(₹ in lakh)

Particulars	As at 30th September, 2024	As at 31st March, 2024
<b>ASSETS</b>		
<b>1 Non-Current Assets</b>		
(a) Property, Plant and Equipment	4,729.24	4,687.01
(b) Capital Work- In- Progress	2,751.96	2,197.17
(c) Intangible assets	959.72	1,082.90
(d) Intangible assets under development	100.29	108.09
	<b>8,541.21</b>	<b>8,075.18</b>
(e) Financial Assets		
(i) Investments	9.22	7.47
(ii) Other Financial Assets	1,673.03	1,675.53
(f) Other Non Current Assets	630.32	746.06
(g) Non Current Tax Assets	106.15	102.97
	<b>2,418.72</b>	<b>2,532.03</b>
<b>2 Current Assets</b>		
(a) Inventories	969.32	957.18
(b) Financial Assets		
(i) Investments	1.86	1.71
(ii) Trade Receivables	3,778.33	2,699.25
(iii) Cash and Cash Equivalents	111.06	594.88
(iv) Loans	5.85	5.66
(v) Other Financial Assets	550.58	341.18
(c) Other Current Assets	448.03	465.36
	<b>5,865.03</b>	<b>5,065.22</b>
<b>Total Assets</b>	<b>16,824.95</b>	<b>15,672.42</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share Capital	3,569.00	3,309.00
(b) Other Equity	6,322.08	3,506.43
<b>Equity attributable to owners of the company</b>	<b>9,891.08</b>	<b>6,815.43</b>
(c) Non - Controlling Interest	(22.47)	11.11
	<b>9,868.61</b>	<b>6,826.54</b>
<b>LIABILITIES</b>		
<b>1 Non-Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	2,329.30	4,290.67
(ii) Lease Liabilities	40.10	125.84
(ii) Other Financial Liabilities	115.20	100.36
(b) Provisions	114.31	182.22
(c) Deferred Tax Liabilities (net)	391.77	382.76
	<b>2,990.68</b>	<b>5,081.85</b>
<b>2 Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	1,020.73	1,366.28
(ii) Lease Liabilities	125.84	82.22
(iii) Trade Payables due to :		
- Micro and Small Enterprise	165.83	103.22
- Other than Micro and Small Enterprise	1,439.38	1,107.06
(iv) Other Financial Liabilities	877.02	828.13
(b) Other Current Liabilities	175.92	125.47
(c) Provisions	160.94	151.63
	<b>3,965.66</b>	<b>3,764.03</b>
<b>Total Equity and Liabilities</b>	<b>16,824.95</b>	<b>15,672.42</b>





**Lyka Labs Limited**  
**Unaudited Consolidated Cash Flow Statement for the Half Year Ended 30th September, 2024**

(₹ in lakh)

Particulars	For the Half year Ended 30th		For the Half year Ended 30th	
	September, 2024		September, 2023	
<b>A. Cash Flow from Operating Activities</b>				
Profit / (Loss) for the year before tax		453.47		(259.13)
<b>Adjusted for</b>				
Depreciation	351.96		706.16	
Interest Income	(9.93)		(70.79)	
Finance Cost	119.01		253.91	
Provision for Doubtful Trade Receivables, Advances, Employee Benefits	37.89		52.66	
Exchange rate fluctuation	(49.58)		(18.13)	
Exceptional Items	-		-	
Return on Investment	(0.15)		(0.84)	
		449.20		922.97
<b>Operating profit before working capital change</b>		902.67		663.84
<b>Changes in Working Capital :</b>				
(Increase) / Decrease in Other Non-Current Financial Assets	2.50		(20.95)	
(Increase) / Decrease in Other Non-Current Assets	115.74		(116.13)	
(Increase) / Decrease in Inventories	(12.14)		(102.92)	
(Increase) / Decrease in Trade and other receivables	(1,033.87)		(928.84)	
(Increase) / Decrease in Other Current Financial Assets	(209.40)		142.20	
(Increase) / Decrease in Other Current Assets	17.33		(147.49)	
(Increase) / Decrease in Non-Current Loans	-		-	
(Increase) / Decrease in Current Loans	(0.19)		(341.20)	
Increase / (Decrease) in Other Non-Current Financial Liabilities	15.00		28.00	
Increase / (Decrease) in Non-Current Provisions	(67.91)		(0.53)	
Increase / (Decrease) in Trade Payables	394.93		277.26	
Increase / (Decrease) in Other Current Financial Liabilities	53.33		(164.27)	
Increase / (Decrease) in Other Current Liabilities	50.45		(42.75)	
Increase / (Decrease) in Current Provisions	(24.21)		(19.05)	
		(698.44)		(1,436.67)
<b>Cash generated from operations</b>		204.23		(772.84)
Net Income Tax Payment	(127.59)	(127.59)	(59.92)	(59.92)
<b>Net cashflow from operating activities (A)</b>		76.64		(832.75)
<b>B. Cashflow for Investing activities</b>				
Purchase of Fixed Assets	(818.00)		(309.77)	
Sale of Fixed Assets	-		-	
Interest Received	9.93		70.79	
<b>Net cash used in Investing activities (B)</b>		(808.07)		(238.98)
<b>C. Cashflow from Financing activities</b>				
Proceed from / (Repayment) of Non Current Borrowings Net	(2,252.30)		(1,924.64)	
Proceed from / (Repayment) of Current Borrowings Net	(96.90)		207.94	
Proceeds from Issue of Equity Shares and warrants (Including Premium)	2,720.25		2,511.00	
Interest Paid	(123.45)		(479.59)	
<b>Net cash used in Financing activities (C)</b>		247.60		314.71
<b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b>		(483.83)		(757.02)
<b>Cash and Cash Equivalents at the beginning of the year</b>				
Cash and Cash Equivalents		25.71		274.19
Earmarked Balances		569.17		896.89
		594.88		1,171.08
<b>Cash and Cash Equivalents at the end of the year</b>				
Cash and Cash Equivalents		25.84		48.94
Deposits with Banks (Rs 85.22 lakhs Lien against Bank Guarantee)		85.22		368.24
		111.06		417.18





**Independent Auditor's Review Report on the Quarterly and Year-to-Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review Report to  
The Board of Directors  
Lyka Labs Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Lyka Labs Limited** ("the Parent"), which includes its subsidiaries (the Parent and its Subsidiaries together referred to as "the Group"), for the quarter ended September 30, 2024 and year-to-date from April 1, 2024 to September 30, 2024 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

**Parent**

- i) Lyka Labs Limited

**Subsidiaries**

- i) Lyka BDR International Limited
- ii) Lyka Exports Limited

5. The accompanying statement includes the interim financial results and other financial information in respect of two subsidiaries, whose interim financial results/ information reflects total assets of Rs. 720.14 lakhs as at September 30, 2024, total revenues of Rs. 10.50 lakhs and Rs. 20.02 lakhs, total net profit/ (loss) after tax of Rs. (56.17) lakhs and Rs. (102.17) lakhs and total comprehensive income of Rs. (54.09) lakhs and Rs. (100.43) lakhs, for the quarter ended September 30, 2024 and year-to-date from April 1, 2024 to September 30, 2024 respectively, and net cash inflow of Rs. 1.90 lakhs as at September 30, 2024, which have been reviewed by us.



6. Based on our review conducted and procedures performed as stated in para 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For D. Kothary & Co.**  
Chartered Accountants  
Firm Registration No. 105335W



**Deepak O. Narsaria**  
(Partner)  
Membership No. 121190



UDIN: 24121190BKBOXJ2832

Place: Mumbai  
Date: 12th November, 2024



**Disclosure of information under Regulation 30 of the SEBI Listing Regulations read with SEBI circular No. SEB/HO/CFD/CFD-PoD- 1/P/CIR/2023/123 dated 13<sup>th</sup> July 2023 with respect to change in Key Managerial Personnel**

**Appointment of Mr. Shekhar R Singh**

Sr. No.	Particular	Details of Change
1	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment
2	Date of appointment / <del>cessation</del> and term of appointment	Date of Appointment: 12-11-2024 Mr. Shekhar R Singh is appointed as Company Secretary & Compliance Officer and designated as a Key Managerial Personnel of the Company with effect from 12 <sup>th</sup> November, 2024
3	Brief Profile ( in case of appointment)	<p><b>Name:</b> Mr. Shekhar R Singh</p> <p><b>Educational Qualification:</b></p> <ul style="list-style-type: none"> <li>▪ Member of the Institute of Company Secretaries ( FCS 12881)</li> <li>▪ B.Com and LL.B from University of Mumbai</li> <li>▪ Post Graduate Diploma in Securities Law from Government Law Collage-Mumbai</li> </ul> <p><b>Background:</b> Mr. Shekhar R Singh is a qualified Company Secretary and law graduate with 18 years of experience in legal and Company Secretarial functions.</p>
4	Disclosure of relationships between Directors (in case of appointment of a director )	Not Applicable

**Detailed composition of the Board Committees (after re-constitution) viz. Audit Committee, Nomination & Remuneration Committee, Stakeholders Relationship Committee and Corporate Social Responsibility Committee**

**Audit Committee**

<b>Sr. No.</b>	<b>Name of Committee Member</b>	<b>Designation in Committee</b>	<b>Category</b>
1	Mr. Babulal Jain	Chairperson	Independent Director
2	Ms. Dhara Shah	Member	Independent Director
3	Mr. Neeraj Golas	Member	Independent Director
4	Mr. Kunal Gandhi	Member	Managing Director

**Nomination & Remuneration Committee**

<b>Sr. No.</b>	<b>Name of Committee Member</b>	<b>Designation in Committee</b>	<b>Category</b>
1	Ms. Dhara Shah	Chairperson	Independent Director
2	Mr. Babulal Jain	Member	Independent Director
3	Mr. Neeraj Golas	Member	Independent Director
4	Mr. Prashant Godha	Member	Non-Executive Director

**Stakeholders Relationship Committee**

<b>Sr. No.</b>	<b>Name of Committee Member</b>	<b>Designation in Committee</b>	<b>Category</b>
1	Mr. Babulal Jain	Chairperson	Independent Director
2	Mr. Neeraj Golas	Member	Independent Director
3	Mr. Kunal Gandhi	Member	Managing Director
4	Mr. Yogesh Shah	Member	Executive Director

**Corporate Social Responsibility Committee**

<b>Sr. No.</b>	<b>Name of Committee Member</b>	<b>Designation in Committee</b>	<b>Category</b>
1	Mr. Kunal Gandhi	Chairperson	Managing Director
2	Ms. Dhara Shah	Member	Independent Director
3	Mr. Neeraj Golas	Member	Independent Director
4	Mr. Yogesh Shah	Member	Executive Director